# Tesamorelin FAQ: Mechanism, Trials, Dosage and FDA Status > Tesamorelin FAQ — direct, cited answers on what it is, how it works, IGF-1, visceral and liver fat, half-life, side effects, blood sugar, and the precise FDA-approval scope. Direct, cited answers to the questions readers ask most about the GHRH analogue. ## What is tesamorelin? A synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH(1-44)) with an N-terminal trans-3-hexenoyl group that resists DPP-IV cleavage; it stimulates the body's own pulsatile growth hormone and raises IGF-1 [3][4]. It is given by subcutaneous injection in the trials and is supplied as the acetate salt [1]. ## What does tesamorelin do? In studies it amplifies endogenous pulsatile growth-hormone secretion, raising IGF-1 and promoting fat breakdown preferentially in visceral fat [1][4]. It is FDA-approved only for HIV-associated lipodystrophy; other uses are off-label [5]. It signals the pituitary rather than supplying growth hormone directly. ## How does tesamorelin work? It binds the GHRH receptor on pituitary somatotrophs (the Gs/cAMP/PKA pathway), driving growth-hormone synthesis and pulsatile release; growth hormone then raises hepatic IGF-1, which together promote visceral-fat breakdown [4][1]. The action begins upstream at the pituitary, not at the fat cell. ## Is tesamorelin a growth hormone? No. Tesamorelin is a GHRH analogue: it tells the pituitary to make and release the body's own growth hormone in pulses, rather than supplying exogenous growth hormone [4]. Working with the body's natural pulsatile rhythm is the defining feature of the molecule [3]. ## How does tesamorelin stimulate growth hormone release? It activates the pituitary GHRH receptor, which raises cAMP via the Gs/adenylyl-cyclase pathway and drives episodic (pulsatile) growth-hormone secretion, modeled in PK-PD analyses [4]. In healthy men, two weeks of dosing raised mean overnight growth hormone by 0.5 ug/L (P=0.004) [4]. ## Does tesamorelin raise IGF-1 levels? Yes. In healthy men IGF-1 rose by 181 ug/L; the pivotal HIV trial reported an 81.0% IGF-1 increase [4][1]. IGF-1 is the downstream growth factor that mediates much of the growth-hormone effect — and the reason long-term oncologic safety is monitored [5]. ## Will tesamorelin help me lose belly fat? In HIV-lipodystrophy trials it selectively reduced visceral abdominal fat (VAT -15.2% at 26 weeks) [1]. It was not studied as a general weight-loss agent, and general fat-loss use is off-label [5]. The studied benefit is specific to deep visceral fat in a defined population. ## How long does it take to see fat loss from tesamorelin? Pivotal HIV-lipodystrophy trials measured visceral-fat reduction at 26 weeks (VAT -15.2% vs +5.0% placebo), with the effect sustained to 52 weeks (about -18%) [1][2]. These timelines come from studied HIV populations, not a general-use claim. ## What happens when you stop taking tesamorelin? Does the fat come back? In the 52-week program, visceral fat reaccumulated after discontinuation, so the reported benefit was contingent on continued dosing [2]. The deep fat returns over weeks once treatment stops; the compound does not appear to durably reset fat storage. ## How long should you cycle tesamorelin / how long can you take it? Trials ran 12-26 weeks up to 52 weeks; a 2024 integrase-inhibitor-era trial dosed for 12 months [1][2][9]. These durations describe study design, not a recommended human cycle — they record how long investigators measured, not a protocol to follow. ## Does tesamorelin work for fat loss in non-HIV users? Pivotal efficacy data are in HIV-positive adults on antiretroviral therapy [1][2]. Generalizability to non-HIV populations is mechanistically plausible but not established by large randomized trials; such use is off-label [5]. Non-HIV human data are limited to a mechanistic study in healthy men [4]. ## Can tesamorelin reduce liver fat? In a JAMA trial of antiretroviral-treated HIV adults, tesamorelin reduced hepatic lipid by a net -2.9% versus placebo; a 2024 INSTI-era trial showed -4.2% versus -0.5%, and a 2019 Lancet HIV trial cut hepatic fat fraction -37% relative to placebo [6][9][7]. These are findings in HIV cohorts. ## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease? A 12-month Lancet HIV trial in HIV patients with NAFLD reduced hepatic fat fraction by -37% relative to placebo; 35% versus 4% reached a hepatic fat fraction below 5% [7]. The authors noted that further study of liver histology is needed. The trial population was HIV-positive. ## How does tesamorelin affect the liver in NAFLD? Beyond lowering hepatic fat, MASLD in HIV follows a more aggressive course, and reviews list tesamorelin among promising HIV-specific therapies [13][14]. Visceral-fat reduction is the proposed mediator of the hepatic benefit — the liver clears as the deep abdominal fat that drives it shrinks [6]. ## What is the half-life of tesamorelin? Plasma exposure is short — population PK clearance is about 1,060 L/h, and secondary sources cite roughly 26-38 minutes [12][5]. The downstream IGF-1 elevation persists across the dosing interval, which supports once-daily administration in the studies [4]. ## How long does tesamorelin stay in your system? The peptide clears from plasma rapidly, but its biological effect (raised IGF-1) outlasts plasma levels [4]; the absorbed fraction rose about 13% by day 14 versus day 1 in PK modeling [12]. The molecule leaves quickly while its growth-signal effect lingers. ## What are the side effects of tesamorelin? Trial-reported effects center on injection-site reactions and growth-hormone-class effects; LiverTox assigns likelihood score E (unlikely liver injury) [5]. Active malignancy, hypersensitivity, and pregnancy are labeled contraindications [5]. Effects were characterized in HIV-lipodystrophy cohorts. ## Does tesamorelin increase the risk of diabetes or affect blood sugar? In healthy men, neither fasting glucose nor insulin-stimulated glucose uptake changed significantly, and over 52 weeks glucose changes were not clinically significant [4][2]. Modest glucose perturbation can occur, so monitoring is warranted in dysglycemia. ## Who should not take tesamorelin / who should avoid it? The FDA label contraindicates active malignancy (it must be complete and inactive first), known hypersensitivity to tesamorelin or its excipients, and pregnancy (animal organogenesis showed hydrocephaly) [5]. These are labeled contraindications for the approved product. ## Is tesamorelin FDA approved? Yes, but only for one indication: reducing excess abdominal visceral fat in HIV-infected adults with lipodystrophy (NDA 022505, 2010) [5]. Every other use, including general or cosmetic fat loss and anti-aging, is off-label. It is also prohibited in sport under WADA category S2. --- A trial console on a dark field — the tesamorelin record read newest panel first, the FDA-approved-for-HIV-lipodystrophy scope flagged before any number and the off-label edge held lit; no clinic at this console and nothing here dosed, dispensed, or sold.